PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
It’s been estimated that about 400 million people worldwide have had long COVID. Some researchers say that number is much ...
Paxlovid use was associated with lower rates of hospitalization and death, particularly among older adults, a new study finds ...
Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.
These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...
Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ...
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
In this study, the authors estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval [CI], ...
Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...